These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 29924959)
1. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC). Radulović P; Krušlin B Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959 [TBL] [Abstract][Full Text] [Related]
2. Expression of the E-cadherin-catenin complex in patients with pancreatic ductal adenocarcinoma. Pryczynicz A; Guzińska-Ustymowicz K; Kemona A; Czyzewska J Folia Histochem Cytobiol; 2010 Jan; 48(1):128-33. PubMed ID: 20529828 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer. Miao Y; Li AL; Wang L; Fan CF; Zhang XP; Xu HT; Yang LH; Liu Y; Wang EH Pathol Oncol Res; 2013 Apr; 19(2):281-6. PubMed ID: 23086683 [TBL] [Abstract][Full Text] [Related]
5. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer. Li YJ; Meng YX; Ji XR Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):471-7. PubMed ID: 14599963 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. Wang OH; Azizian N; Guo M; Capello M; Deng D; Zang F; Fry J; Katz MH; Fleming JB; Lee JE; Wolff RA; Hanash S; Wang H; Maitra A PLoS One; 2016; 11(3):e0152300. PubMed ID: 27023625 [TBL] [Abstract][Full Text] [Related]
7. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma. Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma. Zhao CY; Guo ZJ; Dai SM; Zhang Y; Zhou JJ Tumour Biol; 2013 Oct; 34(5):2983-7. PubMed ID: 23696030 [TBL] [Abstract][Full Text] [Related]
10. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma. Wang L; Lu J; Wu H; Wang L; Liang X; Liang Z; Liu T Diagn Pathol; 2017 May; 12(1):42. PubMed ID: 28558797 [TBL] [Abstract][Full Text] [Related]
11. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867 [TBL] [Abstract][Full Text] [Related]
12. Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma. Siret C; Dobric A; Martirosyan A; Terciolo C; Germain S; Bonier R; Dirami T; Dusetti N; Tomasini R; Rubis M; Garcia S; Iovanna J; Lombardo D; Rigot V; André F Br J Cancer; 2018 Feb; 118(4):546-557. PubMed ID: 29161242 [TBL] [Abstract][Full Text] [Related]
13. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504 [TBL] [Abstract][Full Text] [Related]
14. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model. Gagliano N; Celesti G; Tacchini L; Pluchino S; Sforza C; Rasile M; Valerio V; Laghi L; Conte V; Procacci P World J Gastroenterol; 2016 May; 22(18):4466-83. PubMed ID: 27182158 [TBL] [Abstract][Full Text] [Related]
15. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153 [TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma]. Zhou L; Sheng WW; Shi XY; Zhou JP; Dong M Zhonghua Wai Ke Za Zhi; 2019 Mar; 57(3):206-211. PubMed ID: 30861650 [No Abstract] [Full Text] [Related]
18. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients. Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692 [TBL] [Abstract][Full Text] [Related]
19. Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Karayiannakis AJ; Syrigos KN; Polychronidis A; Simopoulos C Anticancer Res; 2001; 21(6A):4127-34. PubMed ID: 11911306 [TBL] [Abstract][Full Text] [Related]
20. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Cai L; Michelakos T; Ferrone CR; Zhang L; Deshpande V; Shen Q; DeLeo A; Yamada T; Zhang G; Ferrone S; Wang X Oncotarget; 2017 Jun; 8(23):37646-37656. PubMed ID: 28430580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]